{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:13:48Z","timestamp":1786115628031,"version":"build-2736575974"},"reference-count":56,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Metronomic chemotherapy (MCT), understood as continuous, low-dose cytotoxic administration without prolonged drug-free intervals, has become an established strategy in several solid tumors, acting primarily through antiangiogenic, immunomodulatory, and direct cytostatic mechanisms rather than replication-dependent cytotoxicity. Despite an expanding evidence base, including positive randomized trials, validated predictive biomarkers of response remain unavailable. Methods: We searched PubMed\/MEDLINE, Embase, and ClinicalTrials.gov (January 2000 to July 2026) for phase II\/III randomized trials, prospective cohorts, and selected retrospective analyses of MCT in breast cancer, head and neck squamous cell carcinoma, NSCLC, and mCRC, and extracted biomarker data from embedded translational substudies of eligible trials. Results: In breast cancer, phase III SYSUCC-001 (adjuvant metronomic capecitabine, improved DFS in TNBC) and MECCA (metronomic capecitabine plus aromatase inhibitor in HR+\/HER2\u2212 disease) provide the strongest evidence, supported by randomized phase II data for the VEX regimen (METEORA-II) and MCT-anti-PD-1 combinations. TEMPO LUNG established metronomic vinorelbine as effective in platinum-unfit NSCLC, while CAIRO3 confirmed metronomic capecitabine\u2013bevacizumab as an effective mCRC maintenance therapy. Most recently, the phase III TMC-I trial extended positive randomized evidence to head and neck cancer. Candidate biomarkers span angiogenic, immune, tumor proliferative, molecular, pharmacodynamic cytokine, on-treatment clinical (adverse-event-based), and gut\u2013microbiome domains, with FOXC1, circulating endothelial cell kinetics, VEGF pathway markers, and regulatory T-cell dynamics among the most promising; however, none has been prospectively validated in a dedicated confirmatory trial. Conclusions: MCT has moved from empirical use to an evidence-based strategy across multiple tumor types, but the lack of validated predictive biomarkers limits informed patient selection. Future trials should incorporate biomarker-driven designs, particularly FOXC1, endothelial cell kinetics, and immune profiling as co-primary objectives. Defining an MCT-sensitive biological phenotype remains the key translational challenge for the field.<\/jats:p>","DOI":"10.3390\/cancers18152488","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:16:27Z","timestamp":1785766587000},"page":"2488","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictive Biomarkers of Metronomic Chemotherapy Response in Solid Tumors: Chasing an Elusive Signal"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4003-5278","authenticated-orcid":false,"given":"Piotr Jan","family":"Wysocki","sequence":"first","affiliation":[{"name":"Department of Oncology, Jagiellonian University-Medical College, 31-501 Krakow, Poland"},{"name":"Department of Oncology, University Hospital, 31-501 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Kwinta","sequence":"additional","affiliation":[{"name":"Department of Oncology, Jagiellonian University-Medical College, 31-501 Krakow, Poland"},{"name":"Department of Oncology, University Hospital, 31-501 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Wysocka","sequence":"additional","affiliation":[{"name":"Scientific Student Society, Jagiellonian University-Medical College, 31-530 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"ref_1","first-page":"1878","article-title":"Antiangiogenic Scheduling of Chemotherapy Improves Efficacy against Experimental Drug-Resistant Cancer","volume":"60","author":"Browder","year":"2000","journal-title":"Cancer Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1172\/JCI9872","article-title":"Less Is More, Regularly: Metronomic Dosing of Cytotoxic Drugs Can Target Tumor Angiogenesis in Mice","volume":"105","author":"Hanahan","year":"2000","journal-title":"J. Clin. Investig."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrc1369","article-title":"The Anti-Angiogenic Basis of Metronomic Chemotherapy","volume":"4","author":"Kerbel","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Buda-Nowak, A., Kwinta, \u0141., Potocki, P., Micha\u0142owska-Kaczmarczyk, A., S\u0142owik, A., Konopka, K., Streb, J., Koniewski, M., and Wysocki, P.J. (2023). Metronomic Chemo-Endocrine Therapy (FulVEC) as a Salvage Treatment for Patients with Advanced, Treatment-Refractory ER+\/HER2-Breast Cancer\u2014A Retrospective Analysis of Consecutive Patients Data. J. Clin. Med., 12.","DOI":"10.3390\/jcm12041350"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.21037\/cco-2025-aw-129","article-title":"The Phase III MECCA Study on Metronomic Chemo-Endocrine Therapy in Advanced Breast Cancer\u2014The Results That So Many Have Been Waiting For","volume":"15","author":"Wysocki","year":"2026","journal-title":"Chin. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s12325-018-0844-4","article-title":"Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project","volume":"36","author":"Cazzaniga","year":"2019","journal-title":"Adv. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"174","DOI":"10.5603\/OCP.2023.0009","article-title":"Strikingly High Activity of Metronomic Chemotherapy in a Patient with Locally Advanced, Life-Threatening Cutaneous Squamous-Cell Cancer\u2014Case Report and Discussion of the Literature","volume":"19","author":"Kwinta","year":"2023","journal-title":"Oncol. Clin. Pract."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Wysocki, P.J., Lubas, M.T., and Wysocka, M.L. (2022). Metronomic Chemotherapy in Prostate Cancer. J. Clin. Med., 11.","DOI":"10.3390\/jcm11102853"},{"key":"ref_9","first-page":"e00526119","article-title":"Efficacy of Metronomic Chemotherapy in Recurrent Cervical Cancer","volume":"22","author":"Popiela","year":"2026","journal-title":"Oncol. Clin. Pract."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrclinonc.2014.89","article-title":"Metronomics: Towards Personalized Chemotherapy?","volume":"11","author":"Pasquier","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Muraro, E., Vinante, L., Fratta, E., Bearz, A., H\u00f6fler, D., Steffan, A., and Baboci, L. (2023). Metronomic Chemotherapy: Anti-Tumor Pathways and Combination with Immune Checkpoint Inhibitors. Cancers, 15.","DOI":"10.3390\/cancers15092471"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Basar, O.Y., Mohammed, S., Qoronfleh, M.W., and Acar, A. (2024). Optimizing Cancer Therapy: A Review of the Multifaceted Effects of Metronomic Chemotherapy. Front. Cell Dev. Biol., 12.","DOI":"10.3389\/fcell.2024.1369597"},{"key":"ref_13","first-page":"748","article-title":"Metronomic Chemotherapy for Triple Negative Breast Cancer?","volume":"8","author":"Kerbel","year":"2016","journal-title":"Aging"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e70035","DOI":"10.1002\/cai2.70035","article-title":"Metronomic Chemotherapy in Breast Cancer: Unleashing the Potential of Combination Regimens","volume":"4","author":"Liu","year":"2025","journal-title":"Cancer Innov."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"12917","DOI":"10.1073\/pnas.2135406100","article-title":"Thrombospondin 1, a Mediator of the Antiangiogenic Effects of Low-Dose Metronomic Chemotherapy","volume":"100","author":"Bocci","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41581-020-00359-2","article-title":"Clear Cell Renal Cell Carcinoma Ontogeny and Mechanisms of Lethality","volume":"17","author":"Jonasch","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1158\/1078-0432.CCR-09-3343","article-title":"Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial","volume":"16","author":"Lathia","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/j.1464-410X.2006.06376.x","article-title":"Clinical Response to Therapy Targeted at Vascular Endothelial Growth Factor in Metastatic Renal Cell Carcinoma: Impact of Patient Characteristics and Von Hippel-Lindau Gene Status","volume":"98","author":"Rini","year":"2006","journal-title":"BJU Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic Cyclophosphamide Regimen Selectively Depletes CD4+CD25+ Regulatory T Cells and Restores T and NK Effector Functions in End Stage Cancer Patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/jama.2020.23370","article-title":"Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival among Patients with Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial","volume":"325","author":"Wang","year":"2021","journal-title":"JAMA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S1470-2045(25)00545-5","article-title":"Metronomic Capecitabine as Extended Adjuvant Chemotherapy for Early Triple-Negative Breast Cancer (SYSUCC-001): Updated 10-Year Outcomes and Post-Hoc Exploratory Biomarker Analysis from a Randomised, Phase 3 Trial","volume":"26","author":"Yuan","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1038\/s41591-024-03088-2","article-title":"Metronomic Chemotherapy plus Anti-PD-1 in Metastatic Breast Cancer: A Bayesian Adaptive Randomized Phase 2 Trial","volume":"30","author":"Mo","year":"2024","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1200\/JCO.24.00938","article-title":"Metronomic Capecitabine plus Aromatase Inhibitor as Initial Therapy in Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: The Phase III MECCA Trial","volume":"43","author":"Wang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/jamaoncol.2023.2150","article-title":"Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients with Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results from the Phase 2 METEORA-II Randomized Clinical Trial","volume":"9","author":"Munzone","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"103725","DOI":"10.1016\/j.breast.2024.103725","article-title":"Phase II Randomized Trial Comparing Metronomic Anthracycline-Containing Chemotherapy versus Standard Schedule in Untreated HER2 Negative Advanced Breast Cancer (GOIM 21003)","volume":"75","author":"Orlando","year":"2024","journal-title":"Breast"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"103795","DOI":"10.1016\/j.breast.2024.103795","article-title":"Metronomic Chemotherapy Using Capecitabine and Cyclophosphamide in Metastatic Breast Cancer: Efficacy, Tolerability and Quality of Life Results from the Phase II METRO Trial","volume":"78","author":"Larsson","year":"2024","journal-title":"Breast"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"12255","DOI":"10.1038\/s41598-023-39386-x","article-title":"Final Results of the Real-Life Observational VICTOR-6 Study on Metronomic Chemotherapy in Elderly Metastatic Breast Cancer Patients","volume":"13","author":"Trevisan","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"100051","DOI":"10.1016\/j.esmoop.2021.100051","article-title":"Metronomic Oral Vinorelbine in Previously Untreated Advanced Non-Small-Cell Lung Cancer Patients Unfit for Platinum-Based Chemotherapy: Results of the Randomized Phase II Tempo Lung Trial","volume":"6","author":"Camerini","year":"2021","journal-title":"ESMO Open"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Camerini, A., Puccetti, C., Donati, S., Valsuani, C., Petrella, M., Tartarelli, G., Puccinelli, P., and Amoroso, D. (2015). Metronomic Oral Vinorelbine as First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer (MOVE Trial). BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1354-2"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.lungcan.2021.01.005","article-title":"Phase II Clinical Trial with Metronomic Oral Vinorelbine and Tri-Weekly Cisplatin as Induction Therapy, Subsequently Concomitant with Radiotherapy in Patients with Locally Advanced, Unresectable NSCLC. Analysis of Survival and Value of ctDNA","volume":"153","author":"Provencio","year":"2021","journal-title":"Lung Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Pujol, J.-L., Coffy, A., Camerini, A., Kotsakis, A., Mencoboni, M., Gusella, M., Pasini, F., Pezzuto, A., Banna, G.L., and Bilir, C. (2019). An Individual Patient-Data Meta-Analysis of Metronomic Oral Vinorelbine in Metastatic Non-Small Cell Lung Cancer. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0220988"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(14)62004-3","article-title":"Maintenance Treatment with Capecitabine and Bevacizumab in Metastatic Colorectal Cancer (CAIRO3): A Phase 3 Randomised Controlled Trial of the Dutch Colorectal Cancer Group","volume":"385","author":"Simkens","year":"2015","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/ijc.70095","article-title":"Clinical and Biological Determinants of Multimodal Metronomic Chemotherapy Efficacy in Chemo-Refractory Gastrointestinal Cancers","volume":"158","author":"Spehner","year":"2026","journal-title":"Int. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e70174","DOI":"10.1002\/mco2.70174","article-title":"Triplet Regimen of Metronomic Capecitabine plus Antiangiogenic Drug and PD-1 Inhibitor as Later-Line Salvage Treatment for Patients with MSS\/pMMR Metastatic Colorectal Cancer: A Retrospective Study","volume":"6","author":"Yang","year":"2025","journal-title":"MedComm"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Wu, J., Dong, Y., Zhu, W., Meng, J., Zhang, H., Fang, C., and Lin, L. (2025). Capecitabine Metronomic Chemotherapy for Metastatic Colorectal Cancer Patients Reaching NED: A Protocol for a Prospective, Randomized, Controlled Trial. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0320591"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"LBA6007","DOI":"10.1200\/JCO.2026.44.17_suppl.LBA6007","article-title":"Ultra-Low-Dose Immunotherapy plus Oral Metronomic Chemotherapy versus Paclitaxel-Carboplatin in Platinum-Sensitive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Randomized Phase III Trial","volume":"44","author":"Shah","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","article-title":"Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia","volume":"26","author":"Garcia","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Wysocki, P.J., \u0141obacz, M., Potocki, P., Kwinta, \u0141., Micha\u0142owska-Kaczmarczyk, A., S\u0142owik, A., Konopka, K., and Buda-Nowak, A. (2023). Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer. Cancers, 15.","DOI":"10.3390\/cancers15041067"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s12032-017-1040-0","article-title":"Communicative Reprogramming Non-Curative Hepatocellular Carcinoma with Low-Dose Metronomic Chemotherapy, COX-2 Inhibitor and PPAR-Gamma Agonist: A Phase II Trial","volume":"34","author":"Walter","year":"2017","journal-title":"Med. Oncol."},{"key":"ref_40","unstructured":"(2022). CAPER Trial: A Phase Ib Study of Metronomic Cyclophosphamide Run-In Followed by Cyclophosphamide Plus Pembrolizumab in Clear-Cell Metastatic Renal Cell Carcinoma (Standard No. NCT04262427)."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"7652","DOI":"10.1158\/1078-0432.CCR-09-1493","article-title":"Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy plus Bevacizumab","volume":"15","author":"Calleri","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"107346","DOI":"10.1016\/j.oraloncology.2025.107346","article-title":"Evaluating the Prognostic Value of Tumor-Derived Circulating Endothelial Cells and Their Progenitors in Platinum-Refractory Oral Cancer Patients for Response to Triple Metronomic Therapy","volume":"165","author":"Shaikh","year":"2025","journal-title":"Oral Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3892\/etm.2011.253","article-title":"Circulating Endothelial Progenitor Cells in Metronomic Chemotherapy Using Irinotecan and\/or Bevacizumab for Colon Carcinoma: Study of Their Clinical Significance","volume":"2","author":"Murakami","year":"2011","journal-title":"Exp. Ther. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/bjc.2013.398","article-title":"VEGF-A Polymorphisms Predict Progression-Free Survival among Advanced Castration-Resistant Prostate Cancer Patients Treated with Metronomic Cyclophosphamide","volume":"109","author":"Orlandi","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.ccell.2014.11.005","article-title":"Postsurgical Adjuvant Tumor Therapy by Combining Anti-Angiopoietin-2 and Metronomic Chemotherapy Limits Metastatic Growth","volume":"26","author":"Srivastava","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"216441","DOI":"10.1016\/j.canlet.2023.216441","article-title":"Metronomic Chemotherapy, Dampening of Immunosuppressive Cells, Antigen Presenting Cell Activation, and T Cells. A Quartet against Refractoriness and Resistance to Checkpoint Inhibitors","volume":"577","author":"Bravetti","year":"2023","journal-title":"Cancer Lett."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e130748","DOI":"10.1172\/jci.insight.130748","article-title":"Metronomic Capecitabine as an Immune Modulator in Glioblastoma Patients Reduces Myeloid-Derived Suppressor Cells","volume":"4","author":"Peereboom","year":"2019","journal-title":"JCI Insight"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.1158\/1078-0432.CCR-25-0338","article-title":"FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial","volume":"31","author":"Rojo","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10456-012-9260-6","article-title":"Clinical, Pharmacokinetic and Pharmacodynamic Evaluations of Metronomic UFT and Cyclophosphamide plus Celecoxib in Patients with Advanced Refractory Gastrointestinal Cancers","volume":"15","author":"Allegrini","year":"2012","journal-title":"Angiogenesis"},{"key":"ref_50","first-page":"7903","article-title":"Metronomic Chemotherapy Remodel Cancer-Associated Fibroblasts to Decrease Chemoresistance of Gastric Cancer in Nude Mice","volume":"14","author":"Wang","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Guan, X., Ma, F., Sun, X., Li, C., Li, L., Liang, F., Li, S., Yi, Z., Liu, B., and Xu, B. (2020). Gut Microbiota Profiling in Patients with HER2-Negative Metastatic Breast Cancer Receiving Metronomic Chemotherapy of Capecitabine Compared to Those under Conventional Dosage. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00902"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Buda-Nowak, A., Luba\u015b, M., Jurczyk, M., Kwinta, \u0141., Micha\u0142owska-Kaczmarczyk, A., Przywara-Sikora, A., Konopka, K., Koniewski, M., Kad\u0142uczka, J., and Szczerbak, O. (2026). Adverse Events as a Surrogate of Sufficient Pharmacological Exposure in Metronomic Combination Chemotherapy: Extended Real-World Cohort Analysis of the FulVEC Regimen in Metastatic ER+\/HER2\u2212 Breast Cancer. Cancers, 18.","DOI":"10.3390\/cancers18142303"},{"key":"ref_53","first-page":"4342","article-title":"Maximum Tolerable Dose and Low-Dose Metronomic Chemotherapy Have Opposite Effects on the Mobilization and Viability of Circulating Endothelial Progenitor Cells","volume":"63","author":"Bertolini","year":"2003","journal-title":"Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Briasoulis, E., Aravantinos, G., Kouvatseas, G., Pappas, P., Biziota, E., Sainis, I., Makatsoris, T., Varthalitis, I., Xanthakis, I., and Vassias, A. (2013). Dose Selection Trial of Metronomic Oral Vinorelbine Monotherapy in Patients with Metastatic Cancer: A Hellenic Cooperative Oncology Group Clinical Translational Study. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-263"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13058-022-01563-7","article-title":"High Platelet-to-Lymphocyte Ratios in Triple-Negative Breast Cancer Associates with Immunosuppressive Status of TILs","volume":"24","author":"Onagi","year":"2022","journal-title":"Breast Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Giampieri, R., Ziranu, P., Daniele, B., Zizzi, A., Ferrari, D., Lonardi, S., Zaniboni, A., Cavanna, L., Cavanna, G., and Cavanna, M. (2020). From CENTRAL to SENTRAL: Circulating Predictive Biomarkers to Anti-VEGFR Therapy. Cancers, 12.","DOI":"10.3390\/cancers12051330"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2488\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T04:28:05Z","timestamp":1785990485000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":56,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cancers18152488"],"URL":"https:\/\/doi.org\/10.3390\/cancers18152488","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]}}}